Methods, devices, kits and compositions for detecting roundworm, whipworm and hookworm

• US 10,429,388 B2
• Filed: 01/05/2018
• Issued: 10/01/2019
• Est. Priority Date: 06/15/2007
• Status: Active Grant

• Current Assignee: Monsanto Company (Bayer AG), IDEXX Laboratories Incorporated
• Original Assignee: IDEXX Laboratories Incorporated
• Inventors: Elsemore, David Allen, Geng, Jinming, Flynn, Laurie A, Crawford, Michael
• Primary Examiner(s): Navarro, Albert M
• Application Number:
  US15/863,352
• Publication Number:
  US 20180149650A1
• Time in Patent Office: 634 Days
• CPC Class Codes: G01N 2333/43526 from worms
• CPC Class Codes: G01N 2333/4353 from nematodes
• CPC Class Codes: G01N 2469/10 Detection of antigens from microorganism in sample from host
• CPC Class Codes: G01N 33/5308 for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
• CPC Class Codes: G01N 33/56966 Animal cells
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

Methods, devices, kits and compositions for detecting the presence or absence of one or more helminthic coproantigens in a sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of roundworm, whipworm and/or hookworm in a fecal sample from a mammal and may also be able to distinguish between one or more helminth infections. Confirmation of the presence or absence of roundworm, whipworm and/or hookworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated.

Claims

1. An immunocomplex comprising a first antibody specifically bound to a polypeptide, wherein the first antibody is capable of specifically binding to an amino acid sequence of SEQ ID NO:

19-23, 38, or Copro6728.

2. The immunocomplex of claim 1, wherein the polypeptide is obtained from a fecal sample.

3. The immunocomplex of claim 1, wherein the first antibody does not specifically bind to a coproantigen selected from the group consisting of hookworm coproantigen, whipworm coproantigen, and heartworm coproantigen.

4. The immunocomplex of claim 1, wherein the first antibody is labeled.

5. The immunocomplex of claim 1, wherein the immunocomplex is bound to a solid support.

6. The immunocomplex of claim 5, wherein the first antibody or the polypeptide is bound to the solid support.

7. The immunocomplex of claim 6, wherein the solid support forms part of an enzyme-linked immunosorbent assay device.

8. The immunocomplex of claim 7, wherein the enzyme-linked immunosorbent assay device is a lateral flow immunoassay device.

9. The immunocomplex of claim 1, wherein the first antibody is polyclonal.

10. The immunocomplex of claim 1, wherein the first antibody is monoclonal.

11. The immunocomplex of claim 1, further comprising a second antibody bound to the polypeptide of the immunocomplex to form a second immunocomplex.

12. The immunocomplex of claim 11, wherein the second antibody is capable of specifically binding to an amino acid sequence of SEQ ID NO:

19-23, 38, or Copro6728.

13. The immunocomplex of claim 11, wherein the second antibody does not specifically bind to a coproantigen selected from the group consisting of hookworm coproantigen, whipworm coproantigen, and heartworm coproantigen.

14. The immunocomplex of claim 11, wherein the second antibody is labeled.

15. The immunocomplex of claim 11, wherein the second immunocomplex is bound to a solid support.

16. The immunocomplex of claim 15, wherein the first antibody or the polypeptide is bound to the solid support.

17. The immunocomplex of claim 16, wherein the solid support forms part of an enzyme-linked immunosorbent assay device.

18. The immunocomplex of claim 17, wherein the enzyme-linked immunosorbent assay device is a lateral flow immunoassay device.

19. The immunocomplex of claim 11, wherein the first antibody, the second antibody, or both are polyclonal.

20. The immunocomplex of claim 11, wherein the first antibody, the second antibody, or both are monoclonal.

21. The immunocomplex of claim 11, further comprising a third antibody bound to the second antibody of the second immunocomplex to form a third immunocomplex.

22. The immunocomplex of claim 21, wherein the third antibody is labeled.